Navigation Links
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Date:5/11/2009

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

WALTHAM, Mass., May 11 /PRNewswire/ -- Logical Therapeutics, Inc (Logical), a biotechnology company focused on the development of products that treat diseases associated with inflammation, today announced that Peter A. Lankau has been appointed Chief Executive Officer, and has been elected to the Company's Board of Directors. Mr. Lankau was most recently President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company.

"I am excited to be teaming up with such an experienced group of scientists and investors to develop clinically meaningful and novel products for inflammatory diseases," said Mr. Lankau. "Logical Therapeutics' pipeline includes important medicines for the millions of people who suffer from chronic inflammatory conditions. Logical's lead compound, LT-NS001 will be particularly important for patients whose need for non-steroidal anti-inflammatory treatment is complicated by significant gastrointestinal risks."

Mr. Lankau became President and CEO of Endo Pharmaceuticals in 2005, after having served as President and COO since 2003, and SVP of Commercial Business since 2000. Previously, Mr. Lankau was Vice President, Sales and Marketing at Alpharma, Inc. and held various management positions at Rhone-Poulenc Rorer.

"We are delighted to have Peter join the Logical team and our Board of Directors," said Lutz Giebel, Chairman of Logical Therapeutics, Inc., and the Managing Partner of SV Life Sciences Advisers LLC, a lead investor in Logical, "His experience in leading a growth oriented public company, his execution of numerous business development transactions, and his understanding of the commercially important, and value creating elements of drug development, will help propel Logical toward significant business opportunities
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2
(Date:8/1/2014)... August 01, 2014 St. Christopher's Hospital ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , St. Christopher's Hospital for ... for children from birth through 21 years of age. ... of the hospital's specialties, including autism and childhood obesity. ...
(Date:8/1/2014)... A leading dress supplier, Discount-Dress.com, explores a variety of outfits ... lady’s wardrobe fashionable and exciting. Recently, the company has announced ... attract more people, it is now launching a special offer ... 65% off. , “Summer is the season of short bridesmaid ... our collection of ‘ 2014 summer short styles .’ The ...
(Date:8/1/2014)... Haelle HealthDay Reporter , THURDAY, ... necessarily healthier than school cafeteria fare, a new study suggests. ... the lunches third and fourth graders brought from home met ... , "Our findings are similar to results of other studies ... found that high-calorie packaged foods and beverages are more common ...
(Date:8/1/2014)... University] New research shows that people who grew ... have a 16-percent greater risk of experiencing poor health ... member sent to prison. The finding, which accounted for ... high rate of imprisonment may be independently imparting enduring ... "These people were children when this happened, and it ...
(Date:8/1/2014)... 01, 2014 Fresh from Las Vegas market, ... some new and exciting products. With the 2014 Holiday season ... with some exciting new products. There have already been some ... below, but other brands like Cozzia and Inada will be ... Las Vegas Market takes place two times a year and ...
Breaking Medicine News(10 mins):Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Discount-Dress.com’s Top Trend Report: 2014 Summer Short Bridesmaid Dresses Now for Sale 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Jailed family member increases risks for kids' adult health 2Health News:Jailed family member increases risks for kids' adult health 3Health News:A Recap of the 2014 Summer Las Vegas Furniture Market by Emassagechair.com 2Health News:A Recap of the 2014 Summer Las Vegas Furniture Market by Emassagechair.com 3
... evaluating their risk for heart disease are missing a crucial ... University of Rochester Medical Center study published in the June ... that most doctors use to assess risk, known as Framingham ... of low income and/or less than a high school education ...
... , 2009 marks sixth consecutive year of support , ... Inc. announced today that the company has committed to raise ... Walk." The commitment represents the sixth consecutive year of ... , , "Safety-Kleen is firmly committed to its financial ...
... ... ... Sturchio, Chairman, Corporate Council on Africa, and Incoming President, Global Health Council ,Ms. Joan ... Department of State ,Dr. Kate Tulenko, Health Specialist, Coordinator of the Africa Health Workforce ...
... 16 The American Association of Oral ... (D-LA) on introducing S. 1235, the Senate companion ... and Surgery (CARES) Act . The bill would require ... Employee Retirement Income Security Act (ERISA) , ...
... Provide Personal Guide to Help Local Cancer Patients Better ... , , PHILADELPHIA, June 16 The ... at the Kimmel Cancer Center at Jefferson in Philadelphia, ... is the first site to launch in Pennsylvania as ...
... Inventive and Earth-friendly fibers are available to solve customers, needs ... ANSONVILLE, N.C., June 16 "Perpetual Innovation" should bring to ... products but also its process. That,s what Premiere Fibers does. ... www.premierefibers.com as well as a whole ...
Cached Medicine News:Health News:Income, education, important factors in heart disease risk 2Health News:Safety-Kleen Announces $100,000 Commitment to American Heart Association 'Start! Dallas Heart Walk' 2Health News:Building Healthcare Leadership in Africa: A Call to Action 2Health News:Oral and Maxillofacial Surgeons Applaud Senator Mary Landrieu (D-LA) For Introducing Legislation to Require Insurance Coverage for Children With Congenital Deformities 2Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 2Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 3Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 4Health News:Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program 5Health News:Premiere Fibers Unveils New Logo, Names for Innovative Brands 2
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Intended for the quantitative determination of total protein in serum. Reaction: endpoint. Wavelength: 540 nm. Linearity: 12 g/dL (120 g/L). Ready to use liquid reagent....
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
Medicine Products: